• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Many Not Satisfied with Business Analytics Reporting

Article

A majority of radiologists aren’t satisfied with their RIS/ PACS or billing reporting, our recent survey on business analytics found.

This is the first part in a series analyzing the results of a survey conducted on Diagnostic Imaging regarding use of business analytics in radiology. Part I covers responses on satisfaction with current reporting practices.

Are you satisfied with your ability to analyze data from PACS or RIS?

  • 17% - No, I am virtually unable to get data out of their system.
  • 70% - No, I can generate some reports, but the process is manual and time consuming
  • 9% - Yes, analyzing data is easy, I can generate anything I need
  • 2% - Yes, I have real-time, on-demand analytics
  • 2% - Not applicable

Are you satisfied with the reporting from your billing department or billing company?

  • 34% - No, I have very little insight in billing data
  • 30% - No, I receive a reporting package, but it does not provide me enough insight
  • 15% - Yes, billing provides periodic reporting that provides me everything I need
  • 4% - Yes, I have real-time, on-demand analytics
  • 17% - Not applicable

 

The first surprise for me is how many are not satisfied with their current reporting. Eight-seven percent are not satisfied with their RIS or PACS reporting and64 percent are not satisfied with their billing reporting. (The billing figure rises to 77 percent after excluding not applicable responses from the results) I should have expected that so many people find reporting and access to data so difficult, as it has been a hot topic at recent conferences I have attended for AHRA, RBMA and at RSNA.

Additional interesting findings come from looking closer at those who seem dissatisfied with reporting from their RIS/PACS. Seventy percent are able to get some data from RIS/PACS, but it is time consuming. Based on many personal conversations I have had, I interpret this to mean that nearly three-fourths of RIS/PACS have at least an ability to export data to Excel, where it has to be manipulated to make the data meaningful. Seventeen percent are unable to get virtually any insight, which probably means their software offers no reporting or export capabilities.

Compare the RIS/PACS answers to the responses from billing, where 34 percent get virtually no insight from their billing department or company. In coming to a conclusion on this 34 percent who get very little insight, let’s exclude the assumption that their role would not benefit from billing data - those are represented in the “not applicable” answer (17 percent) One-third of respondent then are getting virtually zero insight from billing.

I interpret this high percentage of respondents who are getting virtually zero insight as a combination of a failure of billing systems and internal politics restricting the information.T he 30 percent who do get a billing package, but that does not meet their needs, likely means that the billing systems are designed to capture the transactions - as do the RIS/PACS - but do a poor job of opening up the data for analysis.

In the second part, I will cover why respondents do not invest in business analytics and how they could utilize better insight from the analytics.

David Fuhriman, MBA, CPA, is CEO of Bern Medical

Recent Videos
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.